Physician profile
Erin Blevins
NPI 1386429124
$6,006.85
in general payments reported to CMS, 2019-2025
27 companies · $3,285 in 2025
The $3,285 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $234 · 2024: $2,489 · 2025: $3,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,714 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,714.38 |
| Education | $292.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,324.22 | 2023-2025 | |
| Janssen Biotech, INC. | $1,080.16 | 2024-2025 | Tremfya |
| Incyte Corporation | $467.89 | 2023-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $411.71 | 2024-2025 | |
| Organon LLC | $358.45 | 2024-2025 | Vtama, Hadlima |
| Ucb, INC. | $353.44 | 2023-2025 | Bimzelx |
| Dermavant Sciences, INC. | $326.28 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $228.04 | 2024-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $181.95 | 2024-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $163.67 | 2023-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $154.93 | 2024 | |
| Sun Pharmaceutical Industries INC. | $129.68 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.46 | 2024-2025 | Spevigo, Cyltezo |
| Leo Pharma INC. | $112.09 | 2024-2025 | Adbry, Anzupgo |
| Verrica Pharmaceuticals INC. | $109.79 | 2023-2024 | Ycanth |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $80.07 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $74.55 | 2023-2024 | |
| Pfizer INC. | $74.32 | 2025 | |
| Kyowa Kirin, INC. | $61.09 | 2024-2025 | Poteligeo |
| Biofrontera INC. | $35.19 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $31.06 | 2025 | Sofdra |
| Lilly USA, LLC | $25.77 | 2024 | Taltz, Ebglyss |
| Krystal Biotech INC | $25.48 | 2024 | Vyjuvek |
| Almirall LLC | $24.46 | 2025 | Seysara |
| Smith+Nephew, INC. | $22.59 | 2024 | Grafix Pl |
| Arcutis Biotherapeutics, INC. | $15.01 | 2025 | Zoryve |
| Strata Skin Sciences, INC. | $13.50 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Blevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.